Connect with us
European Gaming Congress 2024

Uncategorized

Next Generation Drug Conjugates Market Worth USD 7.94 Billion to 2031 – Exclusive Report by InsightAce Analytic Pvt. Ltd.

Published

on

next-generation-drug-conjugates-market-worth-usd-794-billion-to-2031-–-exclusive-report-by-insightace-analytic-pvt-ltd.

 
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the “Global Next Generation Drug Conjugates Market – By Type (Peptide Receptor Radionuclide Therapy, Ligand mediated RNAi Conjugate, Ligand Conjugated Anti Sense Medicine and Peptide Drug Conjugate), By Type of Targeting Ligand (Amino Sugar, Peptide, Lipid, Small Molecule and Virus-like Particles), By Type of Payload (Peptide, Small Molecule, Oligonucleotide, Radionuclide), By Type of Therapy (Monotherapy, Combination Therapy), By Route of Administration, By Target Indications, By Region, Trends, Industry Competition Analysis, Revenue and Forecast To 2031.”
According to the latest research by InsightAce Analytic, the Global Next Generation Drug Conjugates Market is valued at US$ 2.61 Bn in 2023, and it is expected to reach US$ 7.94 Bn by 2031, with a CAGR of 15.1% during the forecast period of 2024-2031.
Request for Free Sample Pages: https://www.insightaceanalytic.com/report/next-generation-drug-conjugates-market/2482
Next Generation Drug Conjugates Market Report Scope:

Report Attribute

Specifications

Market Size Value In 2023

USD 2.61 Bn

Advertisement
Stake.com

Revenue Forecast In 2031

USD 7.94 Bn

Growth Rate CAGR

CAGR of 15.1% from 2024 to 2031

Quantitative Units

Advertisement
Stake.com

Representation of revenue in US$ Mn and CAGR from 2024 to 2031

Historic Year

2019 to 2023

Forecast Year

2024-2031

Advertisement
Stake.com

Report Coverage

The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends

Segments Covered

By Type, By Targeting Ligand, By Payload, By Therapy, By Route of Administration, By Indications and By Region

Regional Scope

Advertisement
Stake.com

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country Scope

U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea

Growth of the next-generation drug conjugates market is driven by several factors, such as the recent accelerated approvals of various next-generation drug conjugates and the keen interest shown by the big pharma players in forging strategic alliances with the next-generation drug conjugate developers.
The ever-growing rise in medicare costs, along with the increasing burden of rare disease indications, prompted the stakeholders to look for alternatives to conventional therapies. As a result, the next-generation conjugates combine cytotoxic drugs with targeting agents, enhancing drug efficacy while reducing systemic toxicity. Deeper cellular penetration and permeability have emerged as viable targeted therapeutics for rare disease indications, including cancers.
List of Prominent Players in the Next Generation Drug Conjugates Market:

Advanced Accelerator Applications
Alnylam Pharmaceuticals
Arrowhead Pharmaceuticals
Dicerna Pharmaceuticals
Geron Corporation
Ionis Pharmaceuticals
Dyne Therapeutics, Inc.
Ambrx Biopharma, Inc. (Johnson & Johnson Services, Inc.)
Vincerx Pharma
Tubulis Technologies
Nurix Therapeutics, Inc.
Other Prominent Players

Advertisement
Stake.com

Order 180 Pages Full Report @ https://www.insightaceanalytic.com/buy-report/2482
Market Dynamics:
Drivers:
The growth of the next generation drug conjugates (NGDCs) market is driven by several key factors. Technological advancements, such as improved linker technologies and versatile applications, enhance drug efficacy and safety.
The rising prevalence of chronic diseases, particularly cancer and genetic disorders, fuels demand for targeted therapies. Strategic industry collaborations and acquisitions, like Pfizer’s purchase of Seagen, accelerate innovation and market expansion. Favorable regulatory environments support expedited review processes and clear development guidelines. Additionally, significant investment in research and development, supported by funding and innovative platforms, drives the discovery and optimization of new NGDCs. These combined factors contribute to the rapid advancement and adoption of NGDCs in modern medicine.
Challenges:
The global next-generation drug conjugates market faces several formidable challenges. One of the primary obstacles is the high development cost associated with these therapies. The complex manufacturing processes required for drug conjugates involve sophisticated technology and stringent quality control measures, making scalability difficult and expensive. Additionally, the regulatory landscape presents significant hurdles; furthermore, gaining permission from regulatory bodies like the FDA and EMA is a time-consuming and expensive process that frequently necessitates substantial clinical trials to prove safety and efficacy.
Another major challenge is ensuring the stability and efficacy of drug conjugates. In order to be effective, these therapies must both release the therapeutic agent at the target site in a controlled manner and be stable under physiological conditions. Balancing these requirements while minimizing toxicity is a complex scientific and technical task. Patents and proprietary technology can restrict the capacity of new companies to enter the market and innovate, which further complicates intellectual property issues.
Regional Trends:
The North American next generation drug conjugates market is growing due to advanced healthcare infrastructure and significant R&D investments. Key players in the region are driving innovation in targeted cancer therapies, leveraging cutting-edge technologies for drug conjugation. The increasing cases of cancer and the rising demand for personalized medicine boost the market. Favorable regulatory policies further stimulate market growth, allowing swift approval and commercialization of novel drug conjugates.
Moreover, strategic collaborations between pharmaceutical companies and research institutions fuel the development of next-generation therapies. With a robust pipeline and expanding applications beyond oncology, the North American market for drug conjugates is poised for sustained expansion.
Curious About This Latest Version of The Report? Enquiry Before Buying:https://www.insightaceanalytic.com/enquiry-before-buying/2482
Recent Developments:

In April 2023, Novartis entered into a licensing agreement with 3B Pharmaceuticals. 3B Pharmaceuticals is a German-based company involved in the growth of peptide receptor radionuclide therapy (PRRT) candidates targeting fibroblast activation protein (FAP) receptors.
In March 2023, Japan-based PeptiDream signed strategic partnership with US-based RayzeBio to develop a peptide-radioisotope (RI) conjugate against Glypican-3 (“GPC3”) expressed in liver cancers.
In March 2023, The USFDA accepted Ionis Pharmaceutical’s New Drug Application (NDA) for its investigational antisense medication Eplontersen, which is intended for patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN). After Amvuttra (vutrisiran) from Alnylam, Eplontersen will be the second medication licensed for the treatment of hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).

For More Customization @ https://www.insightaceanalytic.com/customisation/2482
Segmentation of Next Generation Drug Conjugates Market-
Next Generation Drug Conjugates Market- By Type

Peptide Receptor Radionuclide Therapy (Peptide Radionuclide Conjugate)
Ligand-mediated RNAi Conjugate
Ligand Conjugated Antisense Medicine
Peptide Drug Conjugate

Next Generation Drug Conjugates Market- By Targeting Ligand

Advertisement
Stake.com

Amino Sugar
Lipid
Peptide
Small Molecule
Virus-like Particles

Next Generation Drug Conjugates Market- By Payload

Peptide
Small Molecule
Oligonucleotide
Radionuclide

Next Generation Drug Conjugates Market- By Therapy

Monotherapy
Combination Therapy

Advertisement
Stake.com

Next Generation Drug Conjugates Market- By Route of Administration

Intravenous
Subcutaneous
Others

Next Generation Drug Conjugates Market- By Indications

Gastroenteropancreatic Neuroendocrine Tumors
Prostate Cancer
Leptomeningeal Carcinomatosis caused by Breast Cancer Brain Metastases
Hereditary Transthyretin Amyloidosis
Atherosclerotic Cardiovascular Diseases
Severe Hypertriglyceridemia
Hereditary Angioedema
Acute Hepatic Porphyria
Primary Hyperoxaluria
Heterozygous Familial Hypercholesterolemia
Hemophilia
Low-Risk Myelodysplastic Syndrome
Myelofibrosis
Familial Chylomicronemia Syndrome
Alpha-1 Antitrypsin Deficiency Liver Disease

Next Generation Drug Conjugates Market- By Region
North America–

Advertisement
Stake.com

The US
Canada
Mexico

Europe–

Germany
The UK
France
Italy
Spain
Rest of Europe

Asia-Pacific–

China
Japan
India
South Korea
South East Asia
Rest of Asia Pacific

Advertisement
Stake.com

Latin America–

Brazil
Argentina
Rest of Latin America

 Middle East & Africa–

GCC Countries
South Africa
Rest of Middle East and Africa

Why should buy this report:

Advertisement
Stake.com

To receive a comprehensive analysis of the prospects for global next generation drug conjugates market
To receive industry overview and future trends of global next generation drug conjugates market
To analyze the next generation drug conjugates market drivers and challenges
To get information on the next generation drug conjugates market size value (US$ Mn) forecast till 2031
Major Investments, Mergers & Acquisition in global next generation drug conjugates market industry

Other Related Reports Published by InsightAce Analytic:
Antibody Drug Conjugates (ADCs) – Linker and Conjugation Technologies Market 
Conjugation and Labeling Services Market 
Peptide–Drug Conjugates (PDCs) Market
Antibody Discovery Market
The post Next Generation Drug Conjugates Market Worth USD 7.94 Billion to 2031 – Exclusive Report by InsightAce Analytic Pvt. Ltd. appeared first on HIPTHER Alerts.

Continue Reading
Advertisement
Stake.com

Uncategorized

Trusted Experts Unite: IDVerse and TrustID Fuse Best of Breed Technology with Human Expertise

Published

on

trusted-experts-unite:-idverse-and-trustid-fuse-best-of-breed-technology-with-human-expertise

IDVerse, a pioneer in generative AI identity solutions, celebrates a significant milestone as TrustID, a proven expert in identity verification and fraud prevention, joins its growing roster of clients. TrustID, leading certified identity service provider (IDSP) and industry veteran, has chosen IDVerse to further progress the capabilities of its human-in-the-loop identity services, setting a new standard in identity validation and security.
The addition of IDVerse’s automated reinforcement learning into TrustID’s services, supported by TrustID’s unique expert human analysts, enhances the accuracy and reliability of the identity verification processes. This collaboration equips TrustID to continue to offer future-proof verification technologies and fraud prevention services. Customers will benefit from enhanced security features, smoother user onboarding, and robust compliance with regulatory standards.
As deepfake attacks rise, with fraudulent entities using manipulated audio or video to impersonate individuals, TrustID and IDVerse are proactively adapting their systems to counter this threat. Recent data from IDVerse reveals that approximately 1 in 4 fraud attempts involve deepfake media, emphasizing the urgency of addressing this issue.
Tony Machin, CEO of TrustID, said: “We are excited to continue our advancement in identity verification automation with IDVerse and leverage their innovative approach to identity technology. We rigorously tested IDVerse with our own known fraudulent document database and through live data tests to ensure our clients receive only the industry’s best. IDVerse performed significantly better in document capture and fraud analysis than other candidates.”
Machin continued: “Together, we will redefine the standards of digital identity verification and fraud prevention, integrating best-of-breed solutions to drive the most robust and straightforward verification, supported by human experts. Incorporating IDVerse reinforces our position at the forefront of the identity verification market and helps us to say ahead of evolving threats, such as deepfake fraud.”
“At IDVerse, we’re committed to providing the essential building blocks for identity businesses, prioritizing both innovation and ethical AI,” stated Matt Adams, CTO and Co-founder of IDVerse.
Adams continued: “By leveraging the best of computer vision and humans, we address algorithmic bias and ensure compliance with regulations like the EU AI Act and the US White House Executive Order on AI. This approach empowers companies like TrustID to navigate the digital landscape responsibly and with confidence, particularly in combating emerging threats such as deepfake media.”
The partnership between IDVerse and TrustID marks a significant advancement in digital identity verification, combining cutting-edge generative AI with human expertise to provide superior security and user experience.
The post Trusted Experts Unite: IDVerse and TrustID Fuse Best of Breed Technology with Human Expertise appeared first on HIPTHER Alerts.

Continue Reading

Uncategorized

Ying Yong grants interview to Russian newspaper Izvestia

Published

on

ying-yong-grants-interview-to-russian-newspaper-izvestia

 
On June 20, Ying Yong, Chief Grand Prosecutor and Prosecutor General of the Supreme People’s Procuratorate (SPP) of China, granted an interview to the Russian newspaper Izvestia on the sidelines of the 6th Meeting of the Heads of Prosecution Services of the BRICS Countries in St. Petersburg, Russia.
Question: What are the characteristics of criminal cases in China? How do Chinese prosecution authorities deal with them?
Ying: Since the founding of the People’s Republic of China, the Chinese people have created dual miracles of eye-catching economic development and long-term social stability under the leadership of the Communist Party of China (CPC). Along with the development of the economy and society, criminal cases in China have undergone some changes over the past two decades. There are significant changes in the crime structure. There has been a continuous decrease in the total amount and proportion of serious violent crimes such as murder, robbery and kidnapping, while the number and proportion of minor crimes such as dangerous driving and acts by cybercrime accomplices have significantly increased. China is one of the countries with the lowest rates of homicide, firearms and explosive incidents, and other serious criminal offenses in the world.
China has placed a high priority on the development of the rule of law. Law-based governance is a constitutional principle and a fundamental governance strategy of the country. The 20th CPC National Congress held in October 2022 specifically planned for “adhering to comprehensive rule of law and advancing law-based governance in the country”, clearly proposing “comprehensively building a modern socialist country along the path of the rule of law” and “comprehensively promoting law-based governance in all respects”, and highlighting “accelerating the development of a fair, efficient and authoritative socialist judicial system” and “strengthening the legal supervision work of the prosecution authorities”. Under the leadership of the CPC, Chinese prosecution authorities thoroughly implement Xi Jinping Thought on the Rule of Law, earnestly enforce the Constitution and laws, respect and effectively safeguard human rights. They adhere to the principles of a legally prescribed punishment for a specified crime, presumption of innocence, and no guilt without evidence, and comprehensively and accurately implement a criminal policy combining severity with leniency that upholds the practice of being strict when necessary, lenient when appropriate, and punishing according to the offense. They strictly adhere to the system of leniency for those who confess and repent, actively promote the construction of a system with Chinese characteristics for governing minor crimes, explore the comprehensive use of criminal, administrative, civil and other means to hierarchically punish minor crimes, and resolve social conflicts in a timely manner. They are working to establish a crime governance structure that is well-ordered in severity and with differentiated responsibilities, and promote the modernization of the system and capacity for national governance, effectively safeguarding national security, social stability and the well-being of the people.
Question: The theme of the 6th Meeting of the Heads of Prosecution Services of the BRICS Countries is “Modern digital solutions on enforcement of the law: experience of BRICS prosecution services”. What experiences do China’s prosecution authorities have in using digital technology to support case handling?
Ying: I presented the development in this regard in China at the 6th Meeting of the Heads of Prosecution Services of the BRICS Countries. Digital technology is a revolutionary means of law enforcement and justice that can effectively enhance technological content and efficiency in law enforcement and justice work. Currently, China is striving to promote the building of a Digital China. The Chinese government has unveiled a plan for the overall layout of the country’s digital development, formulated laws such as the Cybersecurity Law, Data Security Law, and Personal Information Protection Law. Additionally, China is actively participating in the formulation of the United Nations treaty on cybercrime. China’s prosecution authorities attach great importance to the application of digital technology in judicial case handling, deeply implement a digital prosecution strategy, formulate a plan for digital prosecution development, promote IT application in the rule of law, and effectively construct a mechanism for digital prosecution work that is “business-led, data-integrated, technology-supported and application-focused” to enable the work of legal supervision to improve quality and efficiency. In the prosecution of financial crimes, money laundering, smuggling and other crimes, new technologies such as big data and artificial intelligence are fully utilized to review massive relevant evidence, conduct in-depth analysis of the flow of funds involved, dig deep into upstream and downstream crime clues, accurately charge crimes, and simultaneously trace and recover proceeds. By using data algorithms and technological means such as three-dimensional measurement and imaging for identification, the ability to recognize deeply forged audiovisual materials is enhanced so that clues for high-tech crimes can be effectively identified. In handling public interest litigation cases, technologies such as satellite remote sensing are fully utilized to compare changes in the ecological environment, discover clues of public interest damage in areas such as water bodies, soil, wetland protection, desertification control, and biodiversity protection, and to assess public interest damage and rectification.
China’s prosecution authorities focus on analyzing the characteristics and patterns of cases in performing their duties, construct legal supervision big data models, screen more illegal and criminal clues, refer them to competent authorities for investigation, and, in conjunction with case handling, issue prosecution recommendations to competent authorities to promote plugging loopholes, strengthening of supervision, recovering of losses, and advancing from individual case handling to category supervision and then to litigation source governance. To date, China’s prosecution authorities have jointly developed more than 6,000 legal supervision big data models, discovered over 620,000 supervision clues in groups, strengthened legal supervision, and effectively achieved systematic governance and litigation source governance.
Question: In recent years, what new achievements have been made in cooperation between Chinese and Russian prosecution authorities? What are your expectations for Sino-Russian prosecutorial cooperation?
Ying: In recent years, under the strategic planning and guidance of President Xi Jinping and Russian President Vladimir Putin, prosecution authorities of both countries have maintained high-standard exchanges and cooperation, achieving fruitful results. Within the frameworks of multilateral mechanisms such as the Meeting of the Heads of Prosecution Services of the BRICS Countries and the Prosecutors General Conference of the Member States of Shanghai Cooperation Organization, the two countries’ prosecution authorities have respected each other, communicated in a friendly manner, effectively strengthened law enforcement and judicial cooperation in combating transnational crimes, terrorist crimes, religious extremist crimes, continuously deepened exchanges and cooperation between border region prosecution authorities, and jointly provided strong judicial support for the development and stability of both countries and the region.
Since last year, I have had three friendly, in-depth, and fruitful meetings with His Excellency Russia’s Prosecutor General Igor Krasnov. We have established a good working relationship and deep friendship. Last year, the SPP and the Prosecutor General’s Office of Russia jointly signed a plan for bilateral cooperation for 2023 to 2024, cooperation agreements in the fields of education, research and specific agreements on local prosecution cooperation. Both sides are actively implementing these cooperation agreements, and more pragmatic exchanges and cooperation are steadily advancing. In September and November last year, prosecutors of both countries were sent to each other’s countries for study and visits, from which both sides greatly benefited.
This year marks the 75th anniversary of the establishment of diplomatic relations between China and Russia. In May of this year, after President Putin was re-elected as Russian President, he chose China as the first foreign country to visit during his new term, embarking on a visit to China immediately after taking office as president. President Xi and President Putin met in Beijing, jointly signed and issued a joint statement on deepening the China–Russia comprehensive strategic partnership of cooperation for the new era, charting a blueprint for the development of China–Russia relations in the future at a new historical starting point. The SPP is willing to work with the Prosecutor General’s Office of Russia to further deepen friendly exchanges and pragmatic cooperation between the two countries’ prosecution authorities under the strategic guidance of the two countries’ leaders, and continuously enrich the connotation of China–Russia relations in the new era so as to better benefit both countries and their peoples.
Question: How do you feel about participating in this year’s Meeting of the Heads of Prosecution Services of the BRICS Countries?
Ying: This year’s Meeting of the Heads of Prosecution Services of the BRICS Countries was held in St. Petersburg, and the Russian side made elaborate preparations and thoughtful arrangements for this meeting, making me and my colleagues feel warmly welcomed. During the meeting, prosecutors general from participating countries shared their countries’ concepts, experiences and practices regarding the theme of the meeting, fully consolidating a broad consensus on joining hands to embrace the wave of digital transformation, and demonstrating a broad prospects for exchanges and cooperation in the digital field among prosecution authorities of various countries.
This year’s Meeting of the Heads of Prosecution Services of the BRICS Countries was the first meeting after the successful expansion of the BRICS, with countries such as Iran, Egypt, the United Arab Emirates, and Ethiopia joining the meeting. This fully demonstrates the vitality and vigor of this meeting mechanism and further expands its influence in the international judicial field. China’s prosecution authorities warmly welcomed the new members and also expressed gratitude to the Russian side for its important contributions to the deepening development of this mechanism. We look forward to working with prosecution authorities of BRICS countries, including the Russian side, to uphold the spirit of openness, inclusiveness, cooperation and mutual benefit, seize opportunities and meet upcoming trends, better utilize the power of the rule of law to serve the modernization processes of various countries, and jointly safeguard the interests of all countries and their peoples.
The post Ying Yong grants interview to Russian newspaper Izvestia appeared first on HIPTHER Alerts.

Continue Reading

Uncategorized

Bytes Of Healing: Digital Innovation Meets Patient-Centric Care Through AI/ML

Published

on

bytes-of-healing:-digital-innovation-meets-patient-centric-care-through-ai/ml

 
In the rapidly evolving healthcare landscape, digital innovation driven by Artificial Intelligence (AI) and Machine Learning (ML) is transforming patient care, ushering in a new era of personalized and effective treatment strategies.
Leading this charge is Swapna Nadakuditi, a seasoned expert renowned for her pioneering work at the intersection of data analytics and healthcare.
Swapna Nadakuditi has achieved significant milestones in her career, particularly through her leadership in the Bytes of Healing initiative. Over the past five years, her contributions have been crucial in leveraging AI/ML technologies to enhance patient-centric care. She specializes in utilizing extensive datasets—from medical records to demographic information—to develop predictive models that identify individuals at heightened health risks, such as COPD, diabetes, and CKD. This data-driven approach not only facilitates early disease detection but also enables tailored healthcare solutions that improve patient outcomes.
One of Swapna’s major achievements includes successfully implementing Natural Language Processing (NLP) techniques to extract diagnosis codes from unstructured medical records. This innovation has streamlined clinical documentation processes and enhanced the accuracy of predictive analytics, optimizing healthcare delivery.
In addition to her technical accomplishments, Swapna Nadakuditi has navigated significant challenges inherent in AI/ML integration within healthcare. These challenges include ensuring data privacy compliance, scaling AI solutions using distributed computing frameworks, and fostering interdisciplinary collaboration across data science and healthcare domains. Her proactive approach to overcoming these obstacles underscores her commitment to advancing healthcare through technological innovation.
Swapna’s work has yielded measurable outcomes, including improved risk scoring accuracy, leading to enhanced revenue from risk adjustment and minimized coding errors in healthcare billing. Furthermore, her initiatives have bolstered patient engagement and satisfaction through personalized interventions, augmenting membership growth and service efficiency.
Looking ahead, Swapna Nadakuditi advocates for continued innovation in healthcare, emphasizing the transformative potential of AI technologies integrated with wearable devices and IoT. She predicts that advancements in AI, coupled with regulatory support, will reshape healthcare delivery by making it more efficient, predictive, and patient-centered.
Swapna Nadakuditi’s leadership in Bytes of Healing exemplifies how AI and ML are reshaping healthcare, turning precision medicine and patient-centric care from distant goals into tangible realities. Her pioneering efforts highlight the transformative potential of technology in improving health outcomes and setting new benchmarks for the industry. As she continues to innovate at the intersection of data science and healthcare, Swapna’s vision for the future includes further integration of AI with wearable devices and IoT, promising even more personalized and effective healthcare solutions.
Source: freepressjournal.in
The post Bytes Of Healing: Digital Innovation Meets Patient-Centric Care Through AI/ML appeared first on HIPTHER Alerts.

Continue Reading
Advertisement
Stake.com
Advertisement

Latest News

Trending